Jessica Montes is an associate in the Litigation practice of Paul Hastings and is based in the firm’s New York office. Her practice focuses on internal and government investigations, white collar defense, and compliance counseling, with an emphasis on the life sciences industry, fraud and abuse, and anti-bribery and anti-corruption.
Ms. Montes has extensive experience counseling life sciences companies across a variety of areas, including interactions and engagements with healthcare professionals and government officials, patient support and patient assistance programs, clinical trials, third party relationships, and domestic sales and marketing practices. Ms. Montes has also conducted risk assessments and proactive reviews and developed compliance programs for life sciences clients, including as a secondee at a multinational rare disease company.
Ms. Montes received her law degree from Columbia Law School, where she served on the Columbia Journal of Gender and Law. She earned Bachelor of Arts degrees in Political Science and International Studies from the University of California, Irvine, where she graduated with honors. Ms. Montes is admitted to practice law in New York.
Internal and Government Investigations
Risk Assessments and Diligence
Key Takeaways From the Novartis 345 Million Dollar FCPA Settlement
July 01, 2020
The Trend Continues: As Outward Bound Investments from Japanese Multinationals Continue to Grow, So Do ABAC Compliance and Other Enforcement Risks
June 24, 2020
Part II of II—Not a U.S.-Fits-All-Proposition: Four Key Considerations When Building the Compliance Framework to Go Global with Patient Support
April 17, 2019
Part I of II—Not a U.S.-Fits-All-Proposition: Four Key Considerations When Building the Compliance Framework to Go Global with Patient Support
April 11, 2019
Another Life Sciences Company Announces a Multi-Million Dollar Settlement in the U.S. Department of Justice’s Relentless Pursuit of Donations to Copay Assistance Charities
June 19, 2018
In Light of Digital Realty and the Largest Ever Dodd-Frank Whistleblower Award, Whistleblower Risks Are Up and Company Compliance Programs Are Under Pressure
April 19, 2018
Growth Opportunities Come With Danger: As Japanese Life Sciences Companies’ Outward Bound Investments Continue to Grow, So Do the Significant Compliance
December 09, 2016